Kailera says oral ribupatide IND is active and global Phase 3 will start in 2027

Kailera Therapeutics said its U.S. Investigational New Drug (IND) application for oral ribupatide is active with the Food and Drug Administration, and the company plans to start a global Phase 3 obesity trial for the pill form in the first half of 2027 ^[2]. Ribupatide is an investigational GLP-1 medicine being developed in both injectable and oral forms; it is not currently approved for any use in the United States.

Alongside the oral program, Kailera said its U.S. Phase 2b trial of a high-dose injectable version of ribupatide for obesity has finished enrolling participants, with data expected in mid-2027 ^[2]. A separate, larger global Phase 3 program for the injectable, called KaiNETIC, is on track to enroll more than 4,700 people, with results expected in 2028 ^[2]. The company disclosed these updates as part of its second-quarter 2026 results announcement, though specific financial figures such as quarterly losses or cash reserves were not detailed in the source material available for this story ^[2].

Ribupatide should not be confused with another Kailera-linked molecule, safiglipron (also known as HRS-7535), an oral small-molecule GLP-1 drug developed with Jiangsu Hengrui Pharmaceuticals and Shandong Suncadia Medicine. That program is further along: China's drug regulator recently accepted a marketing application for safiglipron tablets for weight management in adults with obesity or overweight, based on a Phase 3 trial called HARBOR-1 that enrolled 556 adults across 50 centers and met its main goals after 44 weeks of once-daily dosing at 120 mg or 180 mg ^[1]. Earlier studies of safiglipron showed a mean weight loss of 6.63% after 28 days at higher doses in healthy volunteers, compared with 1.18% on placebo ^[1], and in a 16-week Phase 2 trial in people with type 2 diabetes, the drug lowered blood sugar levels (A1C) by up to 1.82 percentage points more than placebo, with weight loss up to 2.63% at the 90 mg dose versus 1.30% for placebo ^[1]. That drug has not been filed for approval in the United States, according to the available source material.

Why it matters for patients

For people currently using approved GLP-1 medicines such as semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), or orforglipron (Foundayo), this update does not change anything about their current treatment. Ribupatide is still in mid-stage and early late-stage testing, and its oral form has not yet begun the large trials needed to support an FDA application ^[2].

The update does show that competition in the oral GLP-1 space is growing, with multiple companies racing to bring pill versions of these drugs to market. An oral option could eventually offer an alternative to weekly injections for some patients, but ribupatide's timeline suggests any approval decision is likely several years out, pending successful completion of Phase 3 trials and FDA review ^[2].

What happens next

Kailera says its global Phase 3 obesity trial for oral ribupatide is planned to begin in the first half of 2027 ^[2]. Data from the fully enrolled U.S. Phase 2b high-dose injectable trial are expected in mid-2027 ^[2]. The larger global Phase 3 KaiNETIC program, targeting more than 4,700 participants, is expected to report data in 2028 ^[2]. Separately, regulatory action on Hengrui and Suncadia's safiglipron tablets in China will depend on that country's review of the recently accepted marketing application ^[1].